BTAI Investment HIGHLIGHTS:
*"Unleashing the Power of Artificial Intelligence Across the Entire R&D Value Chain"
*Later-Stage Pipeline with Multiple Near-Term Milestones
*BXCL501 - First in Class Sublingual Thin Film for Acute Treatment of Agitation(Growing Global Healthcare Issue)
*'Agitation' includes Schizophrenia; Dementia; Delirium; Opiod Withdrawal
*Delivery is 'Thin Film/Mouth' - FDA Fast Track Designation - Rapid Onset; Good Safety; Easy to Administer; Non-Invasive
*Phase 2 Readout 3rd Quarter; Anticipated Phase 3 before End of Year 2019
*BXCL701 - First in Class Oral IO Therapy Targeting Pancreatic Cancer and tNEPC
*Biomarker Driven Development Advanced Pancreatic Cancer with Potential Breakthrough Designation
*Cash/Equivalents: $36.3 million as of 3/31/2019
*Major Shareholders: Artemis; Fidelity; DNCA Finance
*Research Coverage includes Barclays, BMO and UBS
BioXcel Therapeutics Inc. - Company Background:
BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. The company's two most advanced clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer.
Market Capitalization: $175 million
Range - 52 week: $14.79 - $2.41
Current Price: $10.+
Trades on: Nasdaq Capital Markets
Ticker Symbol: BTAI
Website: www.bioxceltherapeutics.com